INTRODUCTION
Conventional economic evaluation typically involves piecewise comparisons of competing technologies at a single isolated point in a broader care pathway. This study assesses the value of simulating whole disease and treatment pathways to provide a common economic basis for informing resource allocation decisions across an entire disease service. This "Whole Disease
Modelling" approach was applied to the evaluation of technologies for the detection, diagnosis, treatment and follow-up of colorectal cancer with the intention of informing NICE's colorectal cancer clinical guideline 1 (see Box 1).
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( was developed using SIMUL8 software (see Figure 1) . The model simulates disease and treatment pathways from preclinical disease through to detection, diagnosis, adjuvant treatment, follow-up, treatments for metastases and supportive care. The model was populated using randomised controlled trials, observational studies, audit data, health utility studies, costing sources and expert opinion. Unobservable natural history parameters were calibrated against published data (incidence, stage at diagnosis, probability obstruction and adenomas prevalence) using Bayesian MCMC methods. Economic analysis was undertaken using (1) standard cost-utility decision rules within each guideline topic, and (2) constrained optimisation across all modelled topics.
Box 1 Topics included in the scope of the NICE colorectal cancer clinical guideline CONCLUSION
This study demonstrates that Whole Disease Modelling is feasible and can allow for the economic analysis of virtually any intervention across a disease service within a consistent conceptual and mathematical infrastructure. The approach may be especially valuable in instances whereby a substantial proportion of a disease service has not previously been subjected to formal economic evaluation.
RESULTS
The NICE guideline included fifteen individual economic evaluation topics. Under usual processes, conventional piecewise economic modelling would have been used to evaluate between one and three guideline topics. In contrast, the Whole Disease Model provided a consistent platform for the economic evaluation of eleven of the fifteen guideline topics, ranging from alternative diagnostic technologies through to cytotoxic treatments for metastatic disease.
The constrained optimisation analysis identified a configuration of colorectal services which was expected to maximise QALY gains without exceeding current expenditure levels. Topic E The sequence of local and systemic treatments in patients presenting with locally-advanced colorectal cancer.
Topic F The sequence of local and systemic treatments in patients presenting with synchronous metastatic disease.
Topic G Effectiveness of pre-operative a) short course radiotherapy and b) chemo-radiotherapy in treating patients with rectal cancer.
Topic H For patients with stage II and III rectal cancer, the indications for adjuvant chemotherapy after surgery.
Topic I
For patients with high-risk stage II colon cancer, the indications for adjuvant chemotherapy after surgery.
Topic J
The sequence of ablation, surgery, regional therapy and systemic therapy, to achieve cure or long-term survival in patients with apparently incurable metastatic disease.
Topic K Clinical indications for performing liver metastasectomy in patients with colorectal cancer metastasised to the liver.
Topic L Clinical indications for performing extrahepatic metastasectomy in patients with colorectal cancer.
Topic M Chemotherapy for patients with advanced and metastatic disease
Topic N Methods and frequencies of follow-up after potentially curative treatment for colorectal cancer.
Topic O Colorectal-specific support for patients diagnosed with colorectal cancer.
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